Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa.

This article presents a case study of a patient with severe hidradenitis suppurativa (HS) who developed secondary haemophagocytic lymphohistiocytosis (HLH) caused by varicella zoster virus (VZV) infection following treatment with upadacitinib. The patient experienced a severe reaction to the VZV infection, including polymorphous exanthema, sepsis, pneumonia, and generalized seizures. The diagnosis of secondary HLH associated with VZV infection was made based on clinical and laboratory findings. The patient was treated with antiviral therapy, immunoglobulins, and glucocorticoids, and underwent radical resection of HS lesions. The article highlights the potential risk of severe adverse events, such as VZV infection and HLH, in patients receiving upadacitinib treatment and emphasizes the importance of close monitoring for herpes zoster complications in these patients. [Extracted from the article]